Premium
Dual antithrombotic therapy in PCI: Potential harm in routine adoption
Author(s) -
Sardar Partha,
Dawn Abbott J.
Publication year - 2019
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27999
Subject(s) - medicine , antithrombotic , observational study , randomized controlled trial , conventional pci , intensive care medicine , p2y12 , population , platelet aggregation inhibitor , aspirin , clopidogrel , myocardial infarction , environmental health
Key Points Randomized clinical trials support the use of dual antithrombotic therapy (DAT) in PCI patients but outcomes in clinical practice are unclear. In this observational study of patients at high risk for thromboembolism and bleeding, routine use of a P2Y12 inhibitor alone compared with DAPT with OAC was associated with a significantly higher risk of ischemic events without a lower risk of bleeding. Future randomized trials and observational analyses of large registries are needed to select the ideal patient population for DAT.